Cancer News and Research

Latest Cancer News and Research

CPTC offers training program for firefighters to help reduce health-related deaths and injuries

Firefighter deaths due to heart attacks may not be due to bad diets, but from exposure to hydrogen cyanide in fire smoke. Nationally, six firefighters have literally dropped dead from heart attacks after coming off of a shift of smoky fires and more than 100 were treated or hospitalized for smoke inhalation since January 1.

21 Jun 2010

Exelixis announces regaining of rights to develop and commercialize XL184

Exelixis, Inc. today announced that it has regained full rights to develop and commercialize XL184. Exelixis and Bristol-Myers Squibb Company entered into a global development collaboration for XL184, the clinically most advanced MET inhibitor, in December 2008. Under the agreement, BMS and Exelixis had originally agreed to certain clinical development plans, and Exelixis maintained key rights regarding timing and funding of current and future clinical trials.

21 Jun 2010

Prototype drug blocks MCL-1 protein that helps tumors survive treatment: Scientists

Scientists at Dana-Farber Cancer Institute have found a way to disable a common protein that often thwarts chemotherapy treatment of several major forms of cancer.

21 Jun 2010

New phase I/IIa clinical trial of AR-42 for blood cancer at OSUCCC-James

For the second time within a year, an experimental drug invented by cancer researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James) is being tested on patients in a clinical trial.

19 Jun 2010

Research findings support the need to establish standards for DFSA care

New toxicology findings reveal the presence of drugs and/or alcohol in 76 per cent of women and men who suspect they were victims of drug-facilitated sexual assault. Of those, 64 per cent did not report voluntarily consuming the drugs found, supporting their belief that they may have been slipped a drug. In addition, unexpected male DNA was found in a substantial number of cases, confirming sexual activity.

19 Jun 2010

Active surveillance sufficient for patients with low-risk prostate cancer

Active surveillance or watchful waiting might be sufficient treatment for patients with prostate cancer that has a low risk of progression, according to a new study published online June 18 in The Journal of the National Cancer Institute.

19 Jun 2010

Hyundai Hope on Wheels announces nationwide initiative to raise funds for childhood cancer research

Hyundai Hope on Wheels, a partnership of Hyundai dealers across the U.S. and Hyundai Motor America, today announced a new nationwide initiative to raise funds to fight childhood cancer. Hyundai dealers have pledged to donate a total of $3 million dollars to Hope on Wheels based on vehicles sold during the month of September (National Childhood Cancer Awareness Month).

19 Jun 2010

ExonHit Therapeutics informs shareholders about Highmark's intention to discontinue coverage of PathFinderTG

ExonHit Therapeutics today informs its shareholders that it learned on June 16, 2010 from RedPath Integrated Pathology that Highmark (the Medicare reimbursement regional antenna for the states of Delaware, District of Columbia, Maryland, New Jersey and Pennsylvania) announced its intention to discontinue coverage of PathFinderTG - Pancreatic cancer, contingent to a complementary assessment of the utility of the product.

19 Jun 2010

New insights into cancer hallmarks in induced pluripotent cells

The therapeutic potential of embryonic stem cells has been an intense focus of study and discussion in biomedical research and has resulted in technologies to produce human induced pluripotent stem cells (hiPSCs). Derived by epigenetic reprogramming of human fibroblasts, these hiPSCs are thought to be almost identical to human embryonic stem cells (hESCs) and provide great promise for patient-tailored regenerative medicine therapies.

19 Jun 2010

AMLU, OPEIU partner with Ed Randall's Bat for the Cure to raise funds for fight against prostate cancer

The Association of Minor League Umpires and its parent organization, Office and Professional Employees International Union, have partnered with "Ed Randall's Bat for the Cure – Strike Out Prostate Cancer" to raise funds for the fight against prostate cancer. This Father's Day weekend, June 19-20, the minor league umpires open their personal checkbooks and donate 1 cent for every pitch thrown in their Minor League Baseball games.

19 Jun 2010

UKCMRI unveils vision for biggest biomedical research, innovation centre in Europe

The UK Centre for Medical Research and Innovation (UKCMRI) has unveiled its vision for the institute, which will be the biggest centre for biomedical research and innovation in Europe.

19 Jun 2010

Study measures relationship between individual exposure to arsenic and mortality risk

More than 20 percent of deaths in a study of 12,000 Bangladeshis were attributable to arsenic exposure from contaminated drinking water, new research reports.

19 Jun 2010

Spectrum Pharmaceuticals adjourns Annual Meeting of Shareholders to July 1, 2010

Spectrum Pharmaceuticals, Inc. today announced that it has adjourned its Annual Meeting of Stockholders to 10:30a.m. Pacific Time, Thursday, July 1, 2010, which will be held at the Company's corporate office located at 157 Technology Drive, Irvine, California, 92618.

19 Jun 2010

CFIDS Association applauds AABB for responding to questions about safety of general blood supply

The CFIDS Association of America commends the AABB (formerly the American Association of Blood Banking) for its actions to protect the safety of the nation's blood supply by recommending that blood collectors actively discourage potential donors who have been diagnosed by a physician with chronic fatigue syndrome (CFS, also known as chronic fatigue and immune dysfunction syndrome, or CFIDS) from donating blood through the use of donor information materials made available at the donation site.

19 Jun 2010

OSI Pharmaceuticals' 2% Senior Subordinated Notes due 2025 to remain convertible through July 19, 2010

OSI Pharmaceuticals, Inc. announced today that its 2% Convertible Senior Subordinated Notes due 2025 are convertible at the option of the holders and will remain convertible at least through July 19, 2010, as provided for in the Indenture governing the notes.

19 Jun 2010

HHS Secretary announces new $250M investment to improve health and well-being of Americans

U.S. Department of Health and Human Services Secretary Kathleen Sebelius today announced $250 million in new Affordable Care Act investments to support prevention activities and develop the nation's public health infrastructure.

19 Jun 2010

Date set for Ryan Phua Memorial Kids' Ride, Burlingame Criterium

The 7th annual Ryan Phua Memorial Kids' Ride, featuring more than 700 kids of all ages, will once again provide one of the key highlights at the 24th annual Burlingame Criterium, set for Sunday, June 27, 2010. The race activities will fill the streets, restaurants and shops of downtown Burlingame with thousands of competitive cyclists, children, volunteers and spectators. Adding to the excitement of Ryan's Ride, the day's multiple races will culminate in a Men's pro event and a separate Women's pro event.

19 Jun 2010

Oncolytics Biotech issued patent that covers methods for treating cell proliferative disorders

Oncolytics Biotech Inc. today announced that it has been granted its 35th U.S. Patent, # 7,731,951 entitled "Viruses for the Treatment of Cellular Proliferative Disorders." The patent claims cover methods for treating cell proliferative disorders by administering modified vaccinia virus to proliferating cells having an activated Ras-pathway.

19 Jun 2010

BioTime announces warrant discount offer

BioTime, Inc. announced today that it is commencing a warrant discount offer under which it will permit holders of its common share purchase warrants expiring October 31, 2010 to exercise their warrants at a discounted price of $1.818 per share, which represents a discount of $0.182 from the regular warrant exercise price of $2.00 per share.

19 Jun 2010

AdnaGen signs option agreement to license specific antibodies to KellBenx

AdnaGen AG, a subsidiary of OncoVista Innovative Therapies, Inc., a high-growth global biotech company developing proprietary, leading-edge early detection and drug technologies to enable safe, targeted personal cancer treatments, today announced that it has entered into an option agreement to license specific antibodies to KellBenx Inc., a New York-based private biotech firm.

19 Jun 2010

Cancer News and Research

Latest Cancer News and Research

CPTC offers training program for firefighters to help reduce health-related deaths and injuries

Exelixis announces regaining of rights to develop and commercialize XL184

Prototype drug blocks MCL-1 protein that helps tumors survive treatment: Scientists

New phase I/IIa clinical trial of AR-42 for blood cancer at OSUCCC-James

Research findings support the need to establish standards for DFSA care

Active surveillance sufficient for patients with low-risk prostate cancer

Hyundai Hope on Wheels announces nationwide initiative to raise funds for childhood cancer research

ExonHit Therapeutics informs shareholders about Highmark's intention to discontinue coverage of PathFinderTG

New insights into cancer hallmarks in induced pluripotent cells

AMLU, OPEIU partner with Ed Randall's Bat for the Cure to raise funds for fight against prostate cancer

UKCMRI unveils vision for biggest biomedical research, innovation centre in Europe

Study measures relationship between individual exposure to arsenic and mortality risk

Spectrum Pharmaceuticals adjourns Annual Meeting of Shareholders to July 1, 2010

CFIDS Association applauds AABB for responding to questions about safety of general blood supply

OSI Pharmaceuticals' 2% Senior Subordinated Notes due 2025 to remain convertible through July 19, 2010

HHS Secretary announces new $250M investment to improve health and well-being of Americans

Date set for Ryan Phua Memorial Kids' Ride, Burlingame Criterium

Oncolytics Biotech issued patent that covers methods for treating cell proliferative disorders

BioTime announces warrant discount offer

AdnaGen signs option agreement to license specific antibodies to KellBenx

Cancer Research - Second Edition eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Cancer News and Research

Latest Cancer News and Research

Cancer Research - Second Edition eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in